UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040981
Receipt number R000046794
Scientific Title Efficacy of propiverine hydrochloride for urinary incontinence afterlaparoscopic radical prostatectomy
Date of disclosure of the study information 2020/07/02
Last modified on 2020/07/02 13:30:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of propiverine hydrochloride for urinary incontinence afterlaparoscopic radical prostatectomy

Acronym

Propiverine HCl after prostatectomy

Scientific Title

Efficacy of propiverine hydrochloride for urinary incontinence afterlaparoscopic radical prostatectomy

Scientific Title:Acronym

Propiverine HCl after prostatectomy

Region

Japan


Condition

Condition

Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The main aim of this study was to clarify the efficacy of propiverine hydrochloride after radical prostatectomy with laparoscopy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary endpoint was the pad-test negative rate at 6 months postoperatively.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Patients in the treatment group received propiverine hydrochloride at a dose of 20 mg/day for 6 months.

Interventions/Control_2

Patients in the control group did not received.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Patients who underwent RALP or LRP at our hospital from April 2013 to December 2017 and who experienced postoperative urinary incontinence, defined as pad gain over 1 g on 1-hour pad test.

Key exclusion criteria

Patients were excluded if they had neurogenic bladder dysfunction, overactive bladder, SUI, urinary tract infection, urethral stricture, glaucoma, severe cardiac disease, renal dysfunction, and/or hepatic dysfunction. Patients were also excluded if they received radiation therapy and/or oral treatment with anticholinergic agents, antidepressants.

Target sample size

98


Research contact person

Name of lead principal investigator

1st name Kojiro
Middle name
Last name Ohba

Organization

Nagasaki University Hospital

Division name

Department of Urology and Renal Transplantation

Zip code

852-8501

Address

Sakamoto 1-7-1, Nagasaki, Japan

TEL

0958197340

Email

ohba-k@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name Kojiro
Middle name
Last name Ohba

Organization

Nagasaki University Hospital

Division name

Department of Urology and Renal Transplantation

Zip code

852-8501

Address

Sakamoto 1-7-1, Nagasaki, Japan

TEL

+81958197340

Homepage URL


Email

ohba-k@nagasaki-u.ac.jp


Sponsor or person

Institute

Nagasaki University Hospital

Institute

Department

Personal name



Funding Source

Organization

Nagasaki University Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagasaki University Hospital

Address

Department of Urology and Renal Transplantation

Tel

0958197340

Email

ohba-k@nagasaki-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

104

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 05 Month 27 Day

Date of IRB

2013 Year 05 Month 28 Day

Anticipated trial start date

2013 Year 06 Month 21 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 07 Month 02 Day

Last modified on

2020 Year 07 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046794


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name